Immunotherapy Firm’s Technology Demonstrates ‘Potential Use in Treating Cancers and Bacterial Infections’ – Streetwise Reports (registration)
|
Immunotherapy Firm’s Technology Demonstrates ‘Potential Use in Treating Cancers and Bacterial Infections’
Streetwise Reports (registration) The trial of Inovio’s dMAb therapeutic against prostate-specific membrane antigen, the results of which were published in Cancer Immunology, Immunotherapy, showed “the construct produced monoclonal antibodies that controlled growth of human prostate … |
|
Immunotherapy Firm’s Technology Demonstrates ‘Potential Use in Treating Cancers and Bacterial Infections’
Streetwise Reports (registration) The trial of Inovio’s dMAb therapeutic against prostate-specific membrane antigen, the results of which were published in Cancer Immunology, Immunotherapy, showed “the construct produced monoclonal antibodies that controlled growth of human prostate … |
Medical Xpress |
CRISPR-Cas9 Screen Points to Potential Vulnerabilities in KRAS-Mutated Colorectal Cancer
GenomeWeb NEW YORK (GenomeWeb) – A team from the University of California, San Diego has uncovered potential vulnerabilities in KRAS-mutated colorectal cancer (CRC) using a CRISPR-Cas9 gene editing screen. In a study published online today in Cancer … Editing genes one by one throughout colorectal cancer cell genome uncovers new drug targetMedical Xpress |
Medical Xpress |
CRISPR-Cas9 Screen Points to Potential Vulnerabilities in KRAS-Mutated Colorectal Cancer
GenomeWeb NEW YORK (GenomeWeb) – A team from the University of California, San Diego has uncovered potential vulnerabilities in KRAS-mutated colorectal cancer (CRC) using a CRISPR-Cas9 gene editing screen. In a study published online today in Cancer … Editing genes one by one throughout colorectal cancer cell genome uncovers new drug targetMedical Xpress |
|
Report: Immune Checkpoint Proteins Are the Focus of Cancer Immunotherapy Development
AJMC.com Managed Markets Network Advancements in the cancer immunotherapy pipeline are leading to the production of immune checkpoint inhibitors, and a recent report from Global Business Intelligence (GBI) Research titled “Cancer Immunotherapies—First-in-Class Pipeline Dominated by … |